TRIGR Therapeutics, Inc

Compass Therapeutics announced statistically significant top-line data on the primary efficacy endpoint for COMPANION-002, its ongoing Phase II/III trial with tovecimig (formerly CTX-009) in combinati

Four new sources of venture capital for biotechnology companies were announced during the first half of May with more than $1.7bn in fresh funding for start-ups and growing early-stage firms. Abingwor

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Kyongbo Inks Antibiotics CMO Pacts With

Out-licensing deals by South Korean companies picked up speed in 2018 after relative sluggishness in the past couple of years. Large out-licensing transactions by biotechs noticeably increased, reflec